Immune checkpoint inhibitors were administered to 26% of the matched patients (N = 14) based upon a ≥ 1% positive tumor cell (equals “low”) expression of PD-L1 by IHC and/or PD-L1 (CD274) amplification (N = 11), TMB-high/intermediate (N = 8), and/or MSI-high (N = 1). The gene discussed is CD274; the disease is neoplasm.